Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon

Catheter Cardiovasc Interv. 1999 Nov;48(3):275-8. doi: 10.1002/(sici)1522-726x(199911)48:3<275::aid-ccd8>3.0.co;2-m.

Abstract

Rotational atherectomy (RA) of complex, calcified lesions has been associated with a high incidence of no reflow ranging from 6%-15% and concomitant myocardial necrosis with adverse prognostic implications. There are no uniform strategies for preventing this complication. The role of intracoronary adenosine for the prevention of this phenomenon during RA has not been fully evaluated. We studied the procedural outcome of 122 patients who underwent RA of complex native coronary artery lesions. Fifty-two patients received no adenosine but a variety of other agents. Seventy patients received intracoronary adenosine boluses (24 to 48 microgram prior to and after each RA run). There was no difference in the type of lesion studied, run time, or Burr to artery ratio (0.6-0.7) between the two groups. Six patients without adenosine experienced no reflow (11.6%), with resultant infarction in the target artery territory, while only 1 of 70 patients (1.4%, P - 0.023) in the adenosine group experienced no reflow. No untoward complications were observed during adenosine infusion. Intracoronary adenosine bolus administered during rotational atherectomy is easy, safe, and may significantly reduce the incidence of no reflow, which may improve the 30-day outcome of this procedure.

Publication types

  • Comparative Study

MeSH terms

  • Adenosine / administration & dosage*
  • Atherectomy, Coronary / methods*
  • Coronary Angiography
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / surgery*
  • Coronary Vessels
  • Female
  • Humans
  • Injections, Intra-Arterial
  • Intraoperative Period
  • Male
  • Postoperative Complications / epidemiology
  • Postoperative Complications / prevention & control*
  • Retrospective Studies
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage*

Substances

  • Vasodilator Agents
  • Adenosine